跳至主要内容
临床试验/NCT00681850
NCT00681850已完成不适用

OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.

AstraZeneca1 个研究点 分布在 1 个国家目标入组 4,027 人开始时间: 2008年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
4,027
试验地点
1
主要终点
HbA1c, LDL-cholesterol, Systolic Blood Pressure

研究概览

简要总结

Demonstrate that the use of benchmarking improves quality of patient care, in particular the control of diabetes, lipids and blood pressure, by determining the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c 14,18, LDL-cholesterol16,18 and Systolic Blood Pressure17,18 versus control group (non-benchmarking group) after 12 months of follow-up.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Provision of informed Consent
  • Patients suffering from diabetes type II, insulin dependent or not insulin dependent.

排除标准

  • Type I diabetes
  • Pregnancy diabetes
  • Hospitalisation, as this is a primary care study
  • Patients who are member of the Belgian Diabetes Convention

结局指标

主要结局

HbA1c, LDL-cholesterol, Systolic Blood Pressure

时间窗: Visit 1; Visit 2 (after approximately 4 months after visit 1); Visit 3 (after approximately 8 months after visit 1); Visit 4 (after approximately 12 months after visit 1)

次要结局

  • Glycaemia, Triglycerides, Total and HDL-Cholesterol, Diastolic Blood Pressure, Waist circumference, Smoking habits, Microalbuminuria, Body Mass Index, Physical activity (Rating scale and step counter), Degree of ophthalmic control and dietary advice(Visit 1Visit 2 (after approximately 4 months after visit 1)Visit 3 (after approximately 8 months after visit 1)Visit 4 (after approximately 12 months after visit 1))

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验